MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669–681
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Carlier, P. G., Marty, B., Scheidegger, O., Loureiro de Sousa, P., Baudin, P.-Y., Snezhko, E., & Vlodavets, D. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160145 · Cited by 186 · cited 3×
“In primary inflammatory myopathies, it can act as an indicator of disease activity.(6) STIR sequences cannot quantify level of edema.”
BackgroundMethodOn the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
Linge, J., Heymsfield, S. B., & Dahlqvist Leinhard, O. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz229 · Cited by 103
Research works printed but not linked: 86
- 10.1002/mus.880110202 · doi:10.1002/mus.880110202
- 10.1016/0895-6111(89)90210-3 · doi:10.1016/0895-6111(89)90210-3
- 10.1002/jmri.21492 · DOI · Paper page
- 10.1007/s00415-017-8547-3 · DOI · Paper page
- 10.1016/j.nmd.2009.02.009 · DOI
- 10.3233/JND-180333 · DOI
- 10.1016/S0960-8966(02)00023-8 · DOI · Paper page
- 10.1212/WNL.0b013e318208811f · doi:10.1212/wnl.0b013e318208811f
- 10.1371/journal.pone.0070993 · DOI · Paper page
- 10.1002/jmri.24726 · DOI · Paper page
- 10.1371/journal.pone.0038779 · DOI
- 10.1016/j.nmd.2015.05.006 · DOI
- 10.1371/journal.pone.0192495 · DOI · Paper page
- 10.2165/00007256-200838120-00003 · DOI · Paper page
- 10.1038/s41598-020-64287-8 · DOI
- 10.1111/joim.12234 · DOI
- 10.1007/s11845-017-1714-9 · DOI
- 10.1002/hep.29797 · DOI · Paper page
- 10.1016/j.jhep.2016.04.021 · DOI · Paper page
- 10.4103/0366-6999.186638 · doi:10.4103/0366-6999.186638
- 10.1016/j.ejrad.2015.06.011 · doi:10.1016/j.ejrad.2015.06.011
- 10.1136/jnnp-2017-316736 · doi:10.1136/jnnp-2017-316736
- 10.1155/2018/3710814 · doi:10.1155/2018/3710814
- 10.1371/journal.pone.0090377 · DOI
- 10.1002/mus.24569 · DOI
- 10.1212/WNL.0000000000000828 · DOI
- 10.1212/WNL.0000000000006887 · DOI
- 10.1002/mus.25385 · doi:10.1002/mus.25385
- 10.1212/WNL.0000000000008009 · DOI
- Holm‐Yildiz S, Permanent muscle weakness in hypokalemic periodic paralysis, Neurology
- 10.1212/WNL.0000000000009068 · DOI
- 10.1007/s00415-012-6733-x · DOI
- 10.1371/journal.pone.0194283 · DOI
- 10.1007/s00256-011-1301-5 · DOI
- 10.1007/s00256-011-1240-1 · DOI
- 10.1016/j.nmd.2016.07.013 · DOI
- 10.1002/ana.24599 · DOI · Paper page
- 10.1212/WNL.0000000000004647 · DOI
- 10.1007/s00415-016-8361-3 · DOI
- 10.1371/journal.pone.0085416 · DOI
- 10.1007/s00415-018-9037-y · DOI
- 10.1002/ana.24743 · doi:10.1002/ana.24743
- 10.1002/mus.26189 · DOI
- 10.1002/ana.25345 · doi:10.1002/ana.25345
- Hooijmans MT, 2017, Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients, NMR Biomed, 30, 10.1002/nbm.3667 · DOI
- 10.1002/mus.26038 · DOI
- Gershman A, 2016, A randomized, double‐blinded, placebo‐controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and biological activity of ATYR1940 in adult patients with facioscapulohumeral muscular dystrophy (FSHD), Neuromuscul Disord, 26, S167, 10.1016/j.nmd.2016.06.293 · doi:10.1016/j.nmd.2016.06.293
- 10.1016/j.ejpn.2007.02.018 · DOI
- 10.1212/WNL.0000000000008168 · DOI
- 10.3233/JND-180341 · DOI
- 10.1007/s00415-011-5937-9 · doi:10.1007/s00415-011-5937-9
- 10.1002/acn3.406 · DOI
- 10.1002/acn3.774 · doi:10.1002/acn3.774
- 10.1212/WNL.0000000000000775 · DOI
- 10.1016/S1474-4422(18)30320-X · DOI
- 10.1212/WNL.0000000000002640 · DOI
- 10.1016/S0197-2456(02)00234-9 · DOI
- 10.1016/j.nmd.2014.01.015 · DOI · Paper page
- 10.1016/j.nmd.2011.06.750 · DOI
- 10.1016/j.nmd.2017.11.017 · DOI
- 10.1002/nbm.4119 · DOI
- 10.1212/WNL.0000000000006214 · DOI
- 10.1007/s00415-016-8350-6 · DOI
- 10.1055/s-0034-1389894 · doi:10.1055/s-0034-1389894
- 10.1016/j.arthro.2015.06.035 · DOI
- 10.1016/j.arthro.2015.11.008 · DOI
- Baudin PY, 2012, Prior knowledge, random walks and human skeletal muscle segmentation, Med Image Comput Comput, 15, 569
- 10.1007/s10334-016-0535-6 · DOI
- 10.2214/AJR.07.2732 · DOI · Paper page
- 10.1002/mus.880040304 · DOI · Paper page
- 10.1002/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M · DOI · Paper page
- 10.1148/radiol.10091547 · DOI · Paper page
- 10.1002/mus.880060502 · DOI
- 10.1002/nbm.2851 · DOI
- 10.1136/jnnp-2013-306350 · DOI
- 10.1016/j.nmd.2016.04.009 · doi:10.1016/j.nmd.2016.04.009
- 10.1007/s00415-016-8311-0 · DOI
- 10.1038/s41598-019-41240-y · DOI
- 10.1007/s00415-011-6393-2 · DOI
- 10.1016/j.nmd.2013.12.012 · DOI
- 10.1002/mus.24629 · DOI
- 10.1212/WNL.0000000000002464 · DOI
- 10.1371/journal.pone.0162542 · DOI
- 10.1371/journal.pone.0183825 · DOI
- 10.3348/kjr.2010.11.3.304 · doi:10.3348/kjr.2010.11.3.304
- Glemser PA, 2017, 23Na MRI and myometry to compare eplerenone vs. glucocorticoid treatment in Duchenne dystrophy, Acta Myol Myopath Cardiomyopath Off J Mediterr Soc Myol, 36, 2
Cited by
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
Bodaghi, A., Fattahi, N., & Ramazani, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13323 · Cited by 336
RetractedLinge, J., Birkenfeld, A. L., & Neeland, I. J. (2024) · Circulation · doi:10.1161/circulationaha.124.067676 · Cited by 180
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
Self-citation
Metadata
- Authors
- Dahlqvist, J. R., Widholm, P., Leinhard, O. D., & Vissing, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-07
- Volume
- 88
- Issue
- 4
- Pages
- 669-681
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3028771292
- Cited by
- 90
- References
- 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy. https://app.cochat.ai/papers/10.1002/ana.25804
- The paper
- Dahlqvist, J. R., Widholm, P., Leinhard, O. D., & Vissing, J. (2020). MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy. Annals of Neurology. https://doi.org/10.1002/ana.25804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.